Hangzhou Hekang Pharmaceutical Co., Ltd.

Main study purpose: This study used melogabalin besylate tablets [test preparation T, specification: 5 mg (calculated in C??H??NO?)] provided by Hangzhou Hekang Pharmaceutical Co., Ltd. as the test preparation, and melogabalin besylate tablets [reference preparation R, trade name: Delijing®, specification: 5 mg (calculated in C??H??NO?)] certified by DAIICHI SANKYO CO., LTD. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under postprandial conditions. Secondary study purpose: To observe the safety of a single oral dose of 5 mg (calculated in C??H??NO?) of melogabalin besylate tablets test preparation or reference preparation in healthy subjects.

Main study purpose: This study used melogabalin besylate tablets [test preparation T, specification: 5 mg (calculated in C??H??NO?)] provided by Hangzhou Hekang Pharmaceutical Co., Ltd. as the test preparation, and melogabalin besylate tablets [reference preparation R, trade name: Delijing®, specification: 5 mg (calculated in C??H??NO?)] certified by DAIICHI SANKYO CO., LTD. as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation after administration under fasting conditions. Secondary study purpose: To observe the safety of a single oral dose of 5 mg (calculated in C??H??NO?) of melogabalin besylate tablets test preparation or reference preparation in healthy subjects.

It was investigated whether healthy subjects took a single oral administration of Bripipiprazole orally disintegrating tablets (test preparation, specification: 2 mg) provided by Hangzhou Hekang Pharmaceutical Co., Ltd. under fasting and postprandial conditions and a single oral administration of the same drug under the same conditions. Pharmacokinetic characteristics of Brevipiprazole orally disintegrating tablets (reference preparation, trade name: Rexulti® OD Tablets, strength: 2 mg) certified by Otsuka Pharmaceutical Co., Ltd., and evaluation of bioequivalence and safety between the two preparations sex.